| Value | ₹2,603 Cr |
|---|
NSE filing, NSE: APLLTD. Summary written from the filing by ALFA Finder's alert engine.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹836.20
- Market cap
- ₹16,437 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 23.7×Sector 41.3×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Other Announcement
Alembic Pharmaceuticals Limited has updated its list of Key Managerial Personnel authorised to determine materiality and make stock exchange disclosures. This update follows a board meeting held on November 4, 2026.
Alembic Pharmaceuticals Partnership
Alembic Pharmaceuticals expanded its strategic collaboration with DifGen Pharmaceuticals to commercialize over 20 complex generic products in the US. The portfolio targets a US$5 billion market.
- From
- DifGen Pharmaceuticals
- Execution
- Initial launches from FY28
Alembic Pharmaceuticals Investor Presentation: Key Takeaways
Q2 FY27 revenue ₹26.03bn (+36% YoY), PAT ₹3.35bn (+81%), EBITDA margin 22% (+520bps). US formulations led growth (+77%).
Alembic Pharmaceuticals Q2 FY27 Results: Net Profit ₹335.2 Cr, Up 81.5% YoY
Alembic Pharmaceuticals Ltd reported revenue from operations of ₹2,604 Cr (+36.3% YoY) and net profit of ₹335.2 Cr (+81.5% YoY) for Q2 FY27.
- Key figure
- Net profit ₹335.2 Cr · +81.5% YoY
Alembic Pharmaceuticals Board Meeting Date
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
Other results update announcements
All →C.E. Info Systems Results Update
C.E. Info Systems reported Q2FY27 revenue growth of 15.8% YoY to ₹131.7 Crore. PAT surged 90.6% to ₹35.3 Crore, driven by strong performance in Automotive and Enterprise segments.
- Value
- ₹131.7 Cr
Varroc Engineering Results Update
Varroc Engineering reported Q2 FY27 consolidated revenue of ₹2,947.9 crore, up 33.6% YoY. The company announced restructuring of Italian operations and an acquisition in Forsee Power India.
- Value
- ₹2,948 Cr
Aimtron Electronics Results Update
Aimtron Electronics reported 83% revenue growth for H1 FY27, reaching INR 224.71 Crore. The company's consolidated unexecuted order book stood at INR 733.27 Crore.
- Value
- ₹224.7 Cr
- Order book
- ₹733.3 Cr
Systematic Industries Results Update
Systematic Industries Limited reported H1 FY27 financial results with a 22.1% revenue increase and 37.6% PAT growth. The company also announced an Rs.82.4 Crore POWERGRID order.
- Value
- ₹312.3 Cr
- From
- POWERGRID
- total installed capacity
- 172000.0 MTPA
Mold-Tek Technologies Results Update
Mold-Tek Technologies Ltd reported strong Q2 FY27 results with PAT rising to ₹9.62 Crore. The company secured new data centre and convention centre projects worth ₹14.10 Crore.
- Value
- ₹120.3 Cr
- From
- Dubai-based fabricator and others
- Order book
- ₹37.60 Cr
Shivalik Bimetal Controls Results Update
Shivalik Bimetal Controls reported a 62% YoY increase in Q2 FY27 consolidated EBITDA to ₹50.2 crore. Consolidated revenue grew 43.9% to ₹197.8 crore during the same period.
- Value
- ₹197.8 Cr